NLNK - NewLink Genetics Corporation
| Previous Close | 1.9300 |
| Open | 1.9100 |
| Bid | 1.8700 x 900 |
| Ask | 1.9200 x 1800 |
| Day's Range | 1.8600 - 1.9500 |
| 52 Week Range | 1.2800 - 2.6000 |
| Volume | 121,985 |
| Avg. Volume | 337,120 |
| Market Cap | 69.775M |
| Beta (3Y Monthly) | 0.75 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.0240 |
| Earnings Date | Oct 30, 2017 - Nov 3, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.00 |
- Zacks
Is the Options Market Predicting a Spike in NewLink Genetics (NLNK) Stock?
Investors need to pay close attention to NewLink Genetics (NLNK) stock based on the movements in the options market lately.
- Simply Wall St.
Could NewLink Genetics Corporation's (NASDAQ:NLNK) Investor Composition Influence The Stock Price?
Every investor in NewLink Genetics Corporation (NASDAQ:NLNK) should be aware of the most powerful shareholder groups...
- GlobeNewswire
NewLink Genetics Provides Corporate Update and Reports Second Quarter 2019 Financial Results
AMES, Iowa, July 30, 2019 -- NewLink Genetics Corporation (NASDAQ:NLNK) (“NewLink Genetics” or the “Company”) today announced financial results for the second quarter ended.
- Simply Wall St.
NewLink Genetics Corporation (NASDAQ:NLNK): What Does Its Beta Value Mean For Your Portfolio?
Anyone researching NewLink Genetics Corporation (NASDAQ:NLNK) might want to consider the historical volatility of the...
- Zacks
Implied Volatility Surging for NewLink Genetics (NLNK) Stock Options
Investors need to pay close attention to NewLink Genetics (NLNK) stock based on the movements in the options market lately.
- Zacks
Celgene (CELG) Hits 52-Week High, Can the Run Continue?
Celgene (CELG) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
- GlobeNewswire
NewLink Genetics Presents Updated NLG802 Results at the Immuno-Oncology 2019 World Congress
NLG802, a prodrug of indoximod, produced significantly higher pharmacokinetic (PK) exposure in patients compared to molar equivalent of indoximod while maintaining encouraging.
- Thomson Reuters StreetEvents
Edited Transcript of NLNK earnings conference call or presentation 8-May-19 8:30pm GMT
Q1 2019 NewLink Genetics Corp Earnings Call
- Associated Press
NewLink: 1Q Earnings Snapshot
On a per-share basis, the Ames, Iowa-based company said it had a loss of 27 cents. The biopharmaceutical company posted revenue of $106,000 in the period. In the final minutes of trading on Wednesday, ...
- GlobeNewswire
NewLink Genetics Reports First Quarter 2019 Financial Results and Provides Clinical Activities Update
AMES, Iowa, May 08, 2019 -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced financial results for the first quarter ended March 31, 2019 and provided an update on.
- GlobeNewswire
NewLink Genetics to Participate in Upcoming Investor and Medical Conferences
AMES, Iowa, May 06, 2019 -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that the company will participate in the following investor and medical conferences:.
- Simply Wall St.
NewLink Genetics Corporation (NASDAQ:NLNK): Earnings Expected To Remain Subdued
NewLink Genetics Corporation's (NASDAQ:NLNK) released its most recent earnings update in December 2018, which indicated that losses became smaller relative to the prior year's level - great news for...
- GlobeNewswire
NewLink Genetics to Host Its First Quarter 2019 Conference Call on May 8, 2019
NewLink Genetics Corporation (NLNK) today announced it will host its first quarter 2019 conference call and webcast at 4:30 PM ET on Wednesday, May 8, 2019, to discuss its first quarter financial results and provide an update of its clinical development activities. Investors and the general public are invited to listen to a live audio webcast of the conference call, which can be accessed five minutes prior to the start of the call by dialing (855) 469-0612 (U.S.) or (484) 756-4268 (international). The conference call will be webcast live and a link can be accessed through the NewLink Genetics website at https://edge.media-server.com/m6/p/df4rgjiz.
- GlobeNewswire
NewLink Genetics Presents Encouraging Phase 2 Results for NLG207 in Ovarian Cancer at AACR 2019
AMES, Iowa, April 02, 2019 -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced results from a Phase 2 study of NLG207, a nanoparticle formulation of the topoisomerase.
- Zacks
The Zacks Analyst Blog Highlights: ANI, Kamada, Genomic Health and NewLink
The Zacks Analyst Blog Highlights: ANI, Kamada, Genomic Health and NewLink
- Zacks
4 Small Biotech Stocks Likely to Witness More Upside in 2019
The biotech space is witnessing a rally so far in 2019. Here we discuss four stocks that are likely to witness a continuation of the uptrend going ahead.
- Thomson Reuters StreetEvents
Edited Transcript of NLNK earnings conference call or presentation 27-Feb-19 9:30pm GMT
Q4 2018 NewLink Genetics Corp Earnings Call
- Simply Wall St.
Do Institutions Own Shares In NewLink Genetics Corporation (NASDAQ:NLNK)?
The big shareholder groups in NewLink Genetics Corporation (NASDAQ:NLNK) have power over the company. Institutions often own shares in more established companies, while it's not unusual to see insiders ownRead More...
- GlobeNewswire
NewLink Genetics Announces Clinical Trial Abstract Presentation at AACR Annual Meeting
AMES, Iowa, Feb. 27, 2019 -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that a late-breaking abstract reporting results from a Phase 2 study of NLG207, a.
- GlobeNewswire
NewLink Genetics Reports Fourth Quarter, Year-End 2018 Financial Results and Provides Update for Clinical Programs
AMES, Iowa, Feb. 27, 2019 -- NewLink Genetics Corporation (NASDAQ:NLNK) today reported consolidated financial results for the fourth quarter and year ended 2018, as well as.
- GlobeNewswire
NewLink Genetics to Host Its Fourth Quarter and Full Year 2018 Financial Results Conference Call on February 27, 2019
NewLink Genetics Corporation (NLNK) today announced that it will release its fourth quarter and full year 2018 financial results on Wednesday, February 27, 2019. NewLink Genetics' senior management team will host the conference call, which will be open to all listeners. The conference call will be webcast live and a link can be accessed through the NewLink Genetics website at https://edge.media-server.com/m6/p/dqg32drc.
- GlobeNewswire
Factors of Influence in 2019, Key Indicators and Opportunity within Marathon Oil, Accuray, United Natural Foods, Systemax, Amgen, and NewLink Genetics — New Research Emphasizes Economic Growth
NEW YORK, Feb. 01, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- GlobeNewswire
NewLink Genetics to Participate in the Immuno-Oncology 360° Conference
Dr. Link’s presentation, “IDO Changes the T-cell Balance in the Tumor Microenvironment,” will occur on Wednesday, February 6th, at 9:15 AM ET, and will include a discussion of immune regulation in the tumor microenvironment and how indoximod’s mechanism of action lends itself to counter multiple elements of immune regulation. NewLink Genetics is a clinical stage biopharmaceutical company focused on developing novel immuno-oncology product candidates to improve the lives of patients with cancer.
- Simply Wall St.
Before You Buy NewLink Genetics Corporation (NASDAQ:NLNK), Consider Its Volatility
If you're interested in NewLink Genetics Corporation (NASDAQ:NLNK), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could Read More...
- Business Wire
NewLink Genetics Presents Encouraging Updated Phase 1 Data with Indoximod Plus Chemotherapy in Frontline AML in an Oral Session at 2018 ASH Annual Meeting
AMES, Iowa & SAN DIEGO-- -- Updated Phase 1 data for indoximod plus standard-of-care chemotherapy in newly diagnosed AML show post-induction minimal residual disease negativity rate of 86% and post-consolidation MRD negativity of 100% Safety data from this study indicate the combination treatment regimen was well tolerated with no regimen limiting toxicities observed NewLink Genetics Corporation announced ...
